Top

Clinical and Experimental Nephrology

Published in:

01-10-2016 | Original Article

Does low peritoneal glucose load protect from the development of left ventricular hypertrophy in peritoneal dialysis patients?

Authors: Kamal Hassan, Fadi Hassan, Dunia Hassan, Saab Anwar, Hassan Shadi

Published in: Clinical and Experimental Nephrology | Issue 5/2016

Abstract

Background

Left ventricular hypertrophy (LVH) is a major predictor of the development of cardiovascular events that is considered the main cause of morbidity and mortality in peritoneal dialysis (PD) patients. This study aimed to evaluate retrospectively the impact of low peritoneal glucose load on left ventricular mass (LVM) in PD patients.

Methods

36 patients who were on continuous ambulatory PD for at least a period of 2 years enrolled in the study. Of them, 23 patients received only glucose-based solutions (GBS) [high peritoneal glucose load group (HPGL group)] from the start of PD, and 13 patients received AAS in combination with GBS when their serum albumin decreased to levels <3.5 g/dl [low peritoneal glucose load group (LPGL group)]. AAS was substituted with 1.36 % GBS when serum albumin rose to ≥3.5 g/dl and restarted when serum albumin fell to <3.5 g/dl. Medical history, physical findings, echocardiographic, laboratory and hydration status data from the first month of PD and after 24 months, were obtained from each patient’s medical records.

Results

Mean LVM index (LVMI) increased in both groups (p ≤ 0.010). The increment in mean LVMI was higher in HPGL group compared to LPGL group (p = 0.006). At 24 months: peritoneal glucose load index (PGLI), fluid overload, mean arterial pressure (MAP), HbA1c and hsCRP were higher in HPGL group (p ≤ 0.010), while 24 h ultrafiltration, weekly Kt/V, serum albumin levels and RRF were higher in LPGL group (p ≤ 0.025). The increment (Δ between the values of each parameter from the start of PD and after 24 months) in PGLI, fluid overload, MAP, HbA1c and hsCRP values were higher in HPGL group (p < 0.001).

Conclusions

Low peritoneal glucose load may be associated with a protective effect from the development of LVH in PD patients.

Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med. 2006;166(17):1884–91.CrossRefPubMed

Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med. 1990;322:1561–6.CrossRefPubMed

Stenvinkel P, Amann K, Ketteler M. Cardiovascular disease in chronic kidney disease. In: Feehally J, Floege J, Johnson RJ, editors. Comprehensive clinical nephrology. 3rd ed. Philadelphia: Mosby Elsevier; 2007. p. 839–52.

Boulanger E, Moranne O, Wautier MP, et al. Biocompatibility of peritoneal dialysis fluids. Nephrol Ther. 2005;1(1):14–22.CrossRefPubMed

Johnson DW, Brown FG, Clarke M, balANZ Trial Investigators, et al. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrol Dial Transpl. 2012;27(12):4445–53.CrossRef

Konings CJ, Kooman JP, Schonck M, et al. Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis. Perit Dial Int. 2002;22(4):477–87.PubMed

Chan CT, Greene T, Chertow GM, et al. Determinants of left ventricular mass in patients on hemodialysis: frequent hemodialysis network (FHN) trials. Circ Cardiovasc Imaging. 2012;5:251–61.CrossRefPubMedPubMedCentral

Wizemann V, Wabel P, Chamney P, et al. The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transpl. 2009;24:1574–9.CrossRef

Voroneanu L, Cusai C, Hogas S, et al. The relationship between chronic volume overload and elevated blood pressure in hemodialysis patients: use of bioimpedance provides a different perspective from echocardiography and biomarker methodologies. Int Urol Nephrol. 2010;42(3):789–97.CrossRefPubMed

10.

Nwafor CE, Adebiyi AA, Ogah OS, Falase AO. Relationship between 24-hour blood pressure pattern and left ventricular structure and function in hypertensive Nigerians. Ethn Dis. 2013;23(4):474–9.PubMed

11.

Monfared A, Salari A, Kazemnezhad E, et al. Association of left ventricular hypertrophy with high-sensitive C-reactive protein in hemodialysis patients. Int Urol Nephrol. 2013;45(6):1679-86.CrossRefPubMed

12.

van der Walt C, Malan L, Uys AS, Malan NT. Low grade inflammation and ECG left ventricular hypertrophy in urban african males: the SABPA study. Heart Lung Circ. 2013;22(11):924–9.CrossRefPubMed

13.

Nwose EU, Butkowski E, Cann NG. Whole blood viscosity determination in diabetes management: perspective in practice. North Am J Med Sci. 2009;1(3):110–3.

14.

Krediet RT, Zuyderhoudt FMJ, Boeschoten EW, Arisz L. Peritoneal permeability to proteins in diabetic and non_diabetic continuous ambulatory peritoneal dialysis patients. Nephron. 1986;42:133–40.CrossRefPubMed

15.

Vonesh EF, Snyder JJ, Foley RN, Collins AJ. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? Kidney Int Suppl. 2006;103:S3–11.CrossRefPubMed

16.

Hassan K, Roguin N, Kaganov Y, Hasan S, Kristal B. Effect of erythropoietin therapy on red cells filterability and left ventricular mass in predialysis patients. Ren Fail. 2005;27(2):177–82.CrossRefPubMed

17.

Devereux RB, Drayer JI, Chien S, et al. Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol. 1984;54(6):592–5.CrossRefPubMed

18.

Hiramatsu T, Hayasaki T, Hobo A, et al. Icodextrin eliminates phosphate and ameliorates cardiac hypertrophy and valvular calcification in patients with end-stage renal disease and diabetes mellitus undergoing peritoneal dialysis. Adv Perit Dial. 2013;29:9–13.PubMed

19.

Hiramatsu T, Hayasaki T, Hobo A, et al. When should icodextrin be started to improve atherosclerosis in peritoneal dialysis patients? Adv Perit Dial. 2013;29:4–8.PubMed

20.

Sav T, Oymak O, Inanc MT, Dogan A, Tokgoz B, Utas C. Effects of twice-daily icodextrin administration on blood pressure and left ventricular mass in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int. 2009;29(4):443–9.PubMed

21.

Hiramatsu T, Furuta S, Kakuta H. Favorable changes in lipid metabolism and cardiovascular parameters after icodextrin use in peritoneal dialysis patients. Adv Perit Dial. 2007;23:58–61.PubMed

22.

Konings CJ, Kooman JP, Schonck M, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int. 2003;63(4):1556–63.CrossRefPubMed

23.

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130(6):461–70.CrossRefPubMed

24.

Twardowski ZJ. Clinical value of standardized equilibration tests in CAPD patients. Blood Purif. 1989;7(2–3):95–108.CrossRefPubMed

25.

Amici G, Mastrosimone S, Da Rin G, Bocci C, Bonadonna A. Clinical validation of PD adequest software: modeling error assessment. Perit Dial Int. 1998;18:317–21.PubMed

26.

Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–8.CrossRefPubMed

27.

Lang RM, Bierig M, Devereux RB, Chamber Quantification Writing AAS groupmerican Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography, et al. Recommendations for chamber quantification: a report from the American society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.CrossRefPubMed

28.

Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med. 1992;117:831–6.CrossRefPubMed

29.

Hur E, Gungor O, Musayev O, et al. Bioimpedance spectroscopy for the detection of hypervolemia in peritoneal dialysis patients. Adv Perit Dial. 2011;27:65–70.PubMed

30.

Hassan K, Hassan F, Hassan D, Hassan Sh, Edgem R, Moshe S, Hassan S. The impact of glucose load on left ventricular mass in peritoneal dialysis patients. Clin Nephrol. 2014;81(3):159–65.CrossRefPubMed

31.

Young GA, Kopple JD, Lindholm B, Vonesh EF, De Vecchi A, Scalamogna A, Castelnova C, Oreopoulos DG, Anderson GH, Bergström J, DiChiro J, Gentile D, Nissenson A, Sakhrani L, Brownjohn AM, Nolph KD, Prowant BF, Algrim CE, Martis LM, Serkes KD. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: an international study. Am J Kidney Dis. 1991;1991(17):462–71.CrossRef

32.

Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int.1999;55:1899–911.CrossRefPubMed

33.

Kopple JD. The National Kidney Foundation K/DOQI clinical practice guidelines for dietary protein intake for chronic dialysis patients. Am J Kidney Dis 2001;38(Suppl 1):S68–S73.

34.

Blumenkrantz MJ, Gahl GM, Kopple JD, Kambar AV, Jones MR, Kessel M, Coburn JW. Protein losses during peritoneal dialysis. Kidney Int. 1981;19:593–602.CrossRefPubMed

35.

Kopple JD, Bernard D, Messana J, Swartz R, Bergstrom J, Lindholm B, Lim V, Brunori G, Leiserowitz M, Bier DM, Stegink LD, Martis L, Boyle CA, Serkes KD, Vonesh E, Jones MR. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int. 1995;47:1148–57.CrossRefPubMed

36.

Bruno M, Bagnis C, Marangella M, Rovera L, Cantaluppi A, Linari F. CAPD with an amino acid dialysis solution: a long-term, cross-over study. Kidney Int. 1989;35:1189–94.CrossRefPubMed

37.

Faller B, Aparicio M, Faict D, De Vos C, De Précigout V, Larroumet N, Guiberteau R, Jones M, Peluso F. Clinical evaluation of an optimized 1.1% amino-acid solution for peritoneal dialysis. Nephrol Dial Transpl. 1995;10:1432–7.

38.

Garibotto G, Sofia A, Canepa A, Saffioti S, Sacco P, Sala MR, Dertenois L, Pastorino N, Deferrari G, Russo R. Acute effects of peritoneal dialysis with dialysates containing dextrose or dextrose and amino acids on muscle protein turnover in patients with chronic renal failure. J Am Soc Nephrol. 2001;12:557–67.PubMed

39.

Tjiong HL1, van den Berg JW, Wattimena JL, Rietveld T, van Dijk LJ, van der Wiel AM, van Egmond AM, Fieren MW, Swart R. Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol. 2005;16(5):1486–93.

40.

Virdis A. Schiffrin EL Vascular inflammation: a role in vascular disease in hypertension? Curr Opin Nephrol Hypertens. 2003;12:181–7.CrossRefPubMed

41.

Wrigley BJ, Lip GY, Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail. 2011;13:1161–71.CrossRefPubMed

42.

Lundsgaard-Hansen P, Blauhut B. Relation of hypoxia and edema of the intestinal wall and skin to colloid osmotic pressure. Anaesthesist. 1988;37:112–9.PubMed

43.

Goncalves S, Pecoits-Filho R, Perreto S, et al. Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transpl. 2006;21:2788–94.CrossRef

44.

Yu Z, Tan BK, Dainty S, Mattey DL, Davies SJ. Hypoalbuminaemia, systemic albumin leak and endothelial dysfunction in peritoneal dialysis patients. Nephrol Dial Transpl. 2012;27(12):4437–45.CrossRef

45.

Rosato E, Gigante A, Gasperini ML, et al. Nutritional status measured by BMI is impaired and correlates with left ventricular mass in patients with systemic sclerosis. Nutrition. 2014;30(2):204–9.CrossRefPubMed

Title: Does low peritoneal glucose load protect from the development of left ventricular hypertrophy in peritoneal dialysis patients?
Authors: Kamal Hassan
Fadi Hassan
Dunia Hassan
Saab Anwar
Hassan Shadi
Publication date: 01-10-2016
Publisher: Springer Japan
Published in: Clinical and Experimental Nephrology / Issue 5/2016
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-015-1198-8

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Does low peritoneal glucose load protect from the development of left ventricular hypertrophy in peritoneal dialysis patients?

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2016

Aichi cohort study of the prognosis in patients newly initiated into dialysis (AICOPP): baseline characteristics and trends observed in diabetic nephropathy

Safety of warfarin therapy in chronic hemodialysis patients: a prospective cohort study

Prediction of urine volume soon after birth using serum cystatin C

Associations among serum trimethylamine-N-oxide (TMAO) levels, kidney function and infarcted coronary artery number in patients undergoing cardiovascular surgery: a cross-sectional study

Risk factors associated with relapse or infectious complications in Japanese patients with microscopic polyangiitis

Extracellular volume expansion and the preservation of residual renal function in Korean peritoneal dialysis patients: a long-term follow up study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page